Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTCELL in Parkinson's Disease
NCT02683629Phase 2Completed
- Sponsor
- Algorae Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Oct 2017
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NTCELL in Parkinson's disease (PD) (2 arms), sponsored by Algorae Pharmaceuticals. Primary endpoint: Incidence of adverse events related to treatment at 26 weeks. Started Feb 2016; status: completed.
02
Drugs
NTCELL
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02683629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683629.